|Videos|February 13, 2013
Introduction: Advances and Issues in NSCLC
Advertisement
Episodes in this series
For High-Definition, Click
In the first installment of the series, the moderator, David R. Gandara, MD, provides an overview of the topics that will be discussed by the panel, which includes: Corey J. Langer, MD, Alan B. Sandler, MD, Mark A. Socinski, MD, and Anne S. Tsao, MD.
Gandara notes that this Peer Exchange discussion will focus on a range of issues and challanges facing physicians who treat patients with lung cancer. Specifically, the panel will examine new therapies and testing for molecular abnormalities and the integration of these test results into the treatment decision making process.
Advertisement
Related to this article
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5